171 related articles for article (PubMed ID: 27257808)
1. Cost of Pediatric Visceral Leishmaniasis Care in Morocco.
Tachfouti N; Najdi A; Alonso S; Sicuri E; Laamrani El Idrissi A; Nejjari C; Picado A
PLoS One; 2016; 11(6):e0155482. PubMed ID: 27257808
[TBL] [Abstract][Full Text] [Related]
2. The direct costs of treating human visceral leishmaniasis in Brazil.
Assis TSM; Rosa DCP; Teixeira EM; Cota G; Azeredo-da-Silva ALF; Werneck G; Rabello A
Rev Soc Bras Med Trop; 2017; 50(4):478-482. PubMed ID: 28954068
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of diagnostic-therapeutic strategies for paediatric visceral leishmaniasis in Morocco.
Alonso S; Tachfouti N; Najdi A; Sicuri E; Picado A
BMJ Glob Health; 2017; 2(3):e000315. PubMed ID: 29018581
[TBL] [Abstract][Full Text] [Related]
4. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil.
Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM
Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324
[TBL] [Abstract][Full Text] [Related]
5. Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment.
Vélez ID; Colmenares LM; Muñoz CA
Rev Inst Med Trop Sao Paulo; 2009; 51(4):231-6. PubMed ID: 19739006
[TBL] [Abstract][Full Text] [Related]
6. Epidemiological and clinical features of visceral leishmaniasis in children in Alicante Province, Spain.
Ramos JM; Clavijo A; Moral L; Gavilan C; Salvador T; González de Dios J
Paediatr Int Child Health; 2018 Aug; 38(3):203-208. PubMed ID: 29790825
[TBL] [Abstract][Full Text] [Related]
7. Visceral leishmaniasis in clinical practice.
Davidson RN
J Infect; 1999 Sep; 39(2):112-6. PubMed ID: 10609527
[No Abstract] [Full Text] [Related]
8. [Mediterranean visceral leishmaniasis in immunocompetent children. Report of two cases relapsed after specific therapy].
Colomba C; Scarlata F; Salsa L; Frasca Polara V; Titone L
Infez Med; 2004 Jun; 12(2):139-43. PubMed ID: 15316302
[TBL] [Abstract][Full Text] [Related]
9. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain?
Medrano FJ; Hernández-Quero J; Jiménez E; Pineda JA; Rivero A; Sánchez-Quijano A; Velez ID; Viciana P; Castillo R; Reyes MJ
AIDS; 1992 Dec; 6(12):1499-503. PubMed ID: 1362880
[TBL] [Abstract][Full Text] [Related]
10. Pediatric visceral leishmaniasis in Albania.
Lita G; Davachi F; Sulcebe G; Bregu H; Basha M
Int J Infect Dis; 2002 Mar; 6(1):66-8. PubMed ID: 12044305
[TBL] [Abstract][Full Text] [Related]
11. Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis.
Pourabbas B; Ghadimi Moghadam A; Pouladfar G; Rezaee Z; Alborzi A
Am J Trop Med Hyg; 2013 May; 88(5):868-71. PubMed ID: 23400573
[TBL] [Abstract][Full Text] [Related]
12. Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.
Meheus F; Boelaert M; Baltussen R; Sundar S
Trop Med Int Health; 2006 Nov; 11(11):1715-24. PubMed ID: 17054752
[TBL] [Abstract][Full Text] [Related]
13. The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs.
Meheus F; Abuzaid AA; Baltussen R; Younis BM; Balasegaram M; Khalil EAG; Boelaert M; Musa AM
Am J Trop Med Hyg; 2013 Dec; 89(6):1146-1153. PubMed ID: 24189368
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
[TBL] [Abstract][Full Text] [Related]
15. Short communication: The cost-effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004.
Vega JC; Sanchez BF; Montero LM; Montaña R; Del Pilar Mahecha M; Dueñes B; Baron AR; Reithinger R
Trop Med Int Health; 2007 Dec; 12(12):1540-4. PubMed ID: 18076562
[TBL] [Abstract][Full Text] [Related]
16. An 8-Year Retrospective Study of Human Visceral Leishmaniasis.
Barbosa JF; de Figueiredo SM; Lyon S; Caligiorne RB
Curr Clin Pharmacol; 2016; 11(4):265-269. PubMed ID: 27659611
[TBL] [Abstract][Full Text] [Related]
17. Inter-current and nosocomial infections among visceral leishmaniasis patients in Ethiopia: an observational study.
Berhe N; Hailu A; Abraham Y; Tadesse Y; Breivik K; Abebe Y
Acta Trop; 2001 Oct; 80(2):87-95. PubMed ID: 11600084
[TBL] [Abstract][Full Text] [Related]
18. Drug regimens for visceral leishmaniasis in Mediterranean countries.
Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
[TBL] [Abstract][Full Text] [Related]
19. [Change in human visceral leishmaniasis treatment in Italy: retrospective study of 630 patients].
Gradoni L; Gramiccia M; Scalone A
Parassitologia; 2004 Jun; 46(1-2):199-201. PubMed ID: 15305716
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human granulocyte-macrophage colony-stimulating factor reverses neutropenia and reduces secondary infections in visceral leishmaniasis.
Badaró R; Nascimento C; Carvalho JS; Badaró F; Russo D; Ho JL; Reed SG; Johnson WD; Jones TC
J Infect Dis; 1994 Aug; 170(2):413-8. PubMed ID: 8035028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
